PTM 201
Alternative Names: PTM-201Latest Information Update: 21 Oct 2022
At a glance
- Originator PanTher Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 29 Sep 2022 Preclinical trials in Solid tumours in USA (unspecified route) (PanTher Therapeutics pipeline, September 2022)